Carverhartman6580

Z Iurium Wiki

Verze z 21. 11. 2024, 23:21, kterou vytvořil Carverhartman6580 (diskuse | příspěvky) (Založena nová stránka s textem „A major advance was made to reduce the side effects of cancer therapy via the elucidation of the tumor-specific lytic path "hyperploid progression-mediated…“)
(rozdíl) ← Starší verze | zobrazit aktuální verzi (rozdíl) | Novější verze → (rozdíl)

A major advance was made to reduce the side effects of cancer therapy via the elucidation of the tumor-specific lytic path "hyperploid progression-mediated death" targeting retinoblastoma (Rb) or p53-mutants defective in G1 DNA damage checkpoint. The genetic basis of human cancers was uncovered through the cloning of the tumor suppressor Rb gene. It encodes a nuclear DNA-binding protein whose self-interaction is regulated by cyclin-dependent kinases. A 3D-structure of Rb dimer is shown, confirming its multimeric status. Rb assumes a central role in cell cycle regulation and the "Rb pathway" is universally inactivated in human cancers. Hyperploidy refers to a state in which cells contain one or more extra chromosomes. Hyperploid progression occurs due to continued cell-cycling without cytokinesis in G1 checkpoint-defective cancer cells. The evidence for the triggering of hyperploid progression-mediated death in RB-mutant human retinoblastoma cells is shown. Hence, the very genetic mutation that predisposes to cancer can be exploited to induce lethality. The discovery helped to establish the principle of targeted cytotoxic cancer therapy at the mechanistic level. By triggering the lytic path, targeted therapy with tumor specificity at the genetic level can be developed. It sets the stage for systematically eliminating side effects for cytotoxic cancer therapy.Diatoms are a reservoir of metabolites with diverse applications and silver nanoparticle (AgNP) from diatoms holds immense therapeutic potentials against pathogenic microbes owing to their silica frustules. In the present study, Chaetoceros sp., Skeletonema sp., and Thalassiosira sp were used for synthesis of AgNP. The average particle size of AgNP synthesized was 149.03 ± 3.0 nm, 186.73 ± 4.9 nm, and 239.46 ± 44.3 nm as reported in DLS whereas 148.3 ± 46.8 nm, 238.0 ± 60.9 nm, and 359.8 ± 92.33 nm in SEM respectively. EDX analysis strongly indicates the confirmation of AgNP displaying a sharp peak of Ag+ ions within the spectra. High negative zeta potential values indicate a substantial degree of stabilization even after three months. The antibacterial efficacy of biosynthesized AgNP tested against Aeromonas sp., Escherichia coli, Bacillus subtilis, Staphylococcus aureus, and Streptococcus pneumonia exhibits broad-spectrum antibacterial activity. This study encourages the synthesis of diatom based AgNP for a variety of applications owing least toxicity and biodegradable nature.Intrauterine contraceptive devices may rarely erode into the urinary bladder, usually shortly after insertion. This case report describes the presentation and management of a copper-bearing intrauterine device which had eroded into the bladder. The patient presented with dysuria, dyspareunia and groin pain. The device had been inserted 10 years previously following a termination of pregnancy. A bladder stone had formed on the arm of the T-shaped device. The calculus was successfully lasered transurethrally and the intrauterine device was removed transvaginally. A urinary catheter was left on free drainage for four weeks and a follow-up cystogram showed no leak. Most complications related to intrauterine devices occur within days or weeks of insertion but in this case the complications presented 10 years later.The use of type II pyrethroids, cypermethrin is becoming a growing concern among environmental research centers. While most studies have attempted to cover the areas of DNA damage and microglia activation following exposure to cypermethin in the adult or postnatal life, less is known about the exact degree of neurotoxicity that results from exposure to transplacental sublethal doses of cypermethrin. Nevirapine Reverse Transcriptase inhibitor To study the transplacental neurotoxicity of cypermethrin, pregnant rats were orally administered 10 % of LD50 (25 mg/kg body weight) cypermethrin, one dose daily for one week during the gestational days 15-21. The pups were investigated at postnatal day7, 14 and 21 after birth. In brain, DNA alterations were detected, astrocytes and microglia quantification were performed and some let7 family member miRNAs are estimated. The results show a gain of three major bands in the range of 350bp to 2100bp with high intensities in cortex exposed to cypermethrin compared with similar pattern indicating unaffected genomic regions in thalamus and hypothalamus at 21days. Moreover, increases in the percentage of GFAP positive astrocytes and IBA1 positive microglia indicate astrogliosis and microgliosis respectively due to cypermethrin treatment in cerebral cortex. For the first time, drastically reduced expression of let7a, b and c members are also associated with gliosis and DNA alterations, which are detected in cerebral cortex, following transplacental neurotoxicity of cypermethrin. Taking together, these results suggest that cypermethrin neurotoxicity may be mediated partly through let7 miRNAs.The biotinidase (BTD) enzyme is essential for recycling biotin, a water-soluble B-complex vitamin that is the coenzyme of four carboxylases involved in fatty acid synthesis, amino acid catabolism and gluconeogenesis. If untreated, total or partial BTD deficiencies lead to an autosomal recessive inherited organic aciduria whose clinical features, mainly presenting in the first years of life, include, seizures, skin rash, and alopecia. Based on residual BTD enzyme activity it is possible to identify partial or total biotinidase deficiency. The incidence of profound and partial biotinidase deficiency worldwide is estimated to be about 1 in 60.000. We report twelve years of experience in the newborn screening of biotinidase deficiency on 466.182 neonates. When a positive screening result occurred, a clinical evaluation was made of the patient and genetic counselling was offered to the family. Molecular analysis the BTD gene was carried out in all recalled neonates. Newborn screening lead to the identification of 75 BTD deficiencies with an incidence of about 16.300 births, ten times higher than the reported worldwide incidence. BTD deficiency was confirmed at a genomic level in all patients, demonstrating a high frequency of the p.(Asp444His) amino acid substitution and the complex allele p.(Ala171Thr)/p.(Asp444His) in the analyzed Italian newborns. Four new mutations (two small deletions, one stop mutation and one missense mutation) and a new combined allelic alteration were identified. Our data suggests that there is a high incidence of the biotinidase defect in the Italian population, most likely due to the high frequency of certain mutations.

Autoři článku: Carverhartman6580 (Graves Frisk)